



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/828,481 - Conf. #4860	
			Filing Date	April 20, 2004	
			First Named Inventor	Carl H. JUNE et al.	
			Art Unit	1632	
			Examiner Name	D. T. Nguyen	
Sheet	1	of	2	Attorney Docket Number	36119.140US3/AM100528

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
ML	AA*	US-5,272,082	12-21-1993	Santoli et al.	
	AB*	US-5,399,346	03-21-1995	Anderson et al.	
	AC*	US-5,443,983	08-22-1995	Ochoa et al.	
	AD*	US-5,733,543	03-31-1998	Nabel et al.	
	AE*	US-5,738,852	04-14-1998	Robinson et al.	
	AF*	US-5,827,642	10-27-1998	Riddell et al.	
	AG*	US-5,858,358	01-12-1999	June et al.	
	AH*	US-6,692,964	02-17-2004	June et al.	
✓	AI*	US-2004-0087025	05-06-2004	June et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
ML	BA	WO-90/05541	05-31-1990	THE REGENTS OF THE UNIVERSITY OF MICHIGAN		
ML	BB	WO-94/12196	06-09-1994	TANOX BIOSYSTEMS, INC.		
	BC	WO-94/29436	12-22-1994	THE UNITED STATES OF AMERICA represented by THE SECRETARY OF THE NAVY		
ML	BD	WO-95/03408	02-02-1995	DANA-FARBER CANCER INSTITUTE		
ML	BE	WO-95/33823	12-14-1995	THE UNITED STATES OF AMERICA, represented by THE SECRETARY OF THE NAVY		
ML	BF	WO-95/34320	12-21-1995	REGENTS OF THE UNIVERSITY OF MINNESOTA		
ML	BG	WO-96/01122	01-18-1996	DANA-FARBER CANCER INSTITUTE		
ML	BH	WO-96/02646	02-01-1996	CYTOTHERAPEUTICS, INC.		
ML	BI	WO-96/06942	03-07-1996	MAX-PLANCK- GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	<i>Maric Keavitt</i>	Date Considered	03-07-06
-----------------------	----------------------	--------------------	----------

5412827

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				Application Number	10/828,481 – Conf. #4860
				Filing Date	April 20, 2004
				First Named Inventor	Carl H. JUNE et al.
				Art Unit	1632
				Examiner Name	D. T. Nguyen
Sheet	2	of	2	Attorney Docket Number	36119.140US3/AM100528

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
ML	CA	Cann et al., "High Efficiency Transfection of Primary Human Lymphocytes and Studies of Gene Expression," <i>Oncogene</i> , 3:122-128 (1988)	
ML	CB	Coghlan, "Gene Dream Fades Away" <i>New Scientist</i> , 148: 14-15 (1995)	
ML	CC	Crystal, "Transfer of Genes to Humans: Early Lessons and Obstacles to Success" <i>Science</i> , 270:404-410 (1995)	
ML	CD	Fausser, "Long-Term Expression of Gene Introduction into Normal Human T-Lymphocytes by Retroviral-Mediated Gene Transfer," <i>Journal of Cellular Biochemistry</i> , 45:353-358 (1991)	
ML	CE	Finer et al., "kat: A High-Efficiency Retroviral Transduction System for PRIMARY HUMAN T Lymphocytes," <i>Blood</i> , 83(1):43-50 (1994)	
ML	CF	Guba et al., "Interleukin-3 Gene Induction in Normal Human T Cells Via Stimulation of CD3 and CD28," <i>Clinical Research</i> , 37(4) (1989)	
ML	CG	Gunzburg et al., "Virus Vector Design in Gene Therapy" <i>Molecular Medicine Today</i> , 410-417 (1995)	
ML	CH	Lowenthal et al., "Tumor Necrosis Factor $\alpha$ Induces Proteins that Bind Specifically to kB-like Enhancer Elements and Regulate Interleukin 2 Receptor $\alpha$ -chain Gene Expression in Primary Human T Lymphocytes," <i>PNAS USA</i> , 86:2331-2335 (1989)	
ML	CI	Mastrangelo et al. "Gene Therapy for Human Cancer: An Essay for Clinicians" <i>Seminars In Oncology</i> , 23(1):4-21 (1996)	
ML	CJ	Novak et al., "In Vitro Transfection of Fresh Thymocytes and T Cells Shows SUBset-Specific Expression of Viral Promoters," <i>Molecular and Cellular Biology</i> , 12:1515-1527 (1992)	
ML	CK	Park et al., "Transcriptional Regulation of Interleukin 3 (IL3) in Primary Human T Lymphocytes," <i>Journal of Biological Chemistry</i> , 268(9):6299-6308 (1993)	
ML	CL	Philip et al., "Efficient and Sustained Gene Expression in Primary T Lymphocytes and Primary and Cultured Tumor Cells Mediated by Adeno-Associated Virus Plasmid DNA Complexed to Cationic Liposomes," <i>Molecular and Cellular Biology</i> , 14:2411-2418 (1994)	
ML	CM	Tiberghien et al., "Ganciclovir Treatment of Herpes Simplex Thymidine Kinase-Transduced Primary T Lymphocytes: An Approach for Specific In Vivo Donor T-Cell Depletion After Bone Marrow Transplantation?" <i>Blood</i> , 84(4):1333-1341 (1994)	

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Applicant's unique citation designation number (optional). <sup>3</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	March 07-06
--------------------	---	-----------------	-------------

5412827



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet	1	of	1	Attorney Docket Number	36119.140 US3
-------	---	----	---	------------------------	---------------

**Complete if Known**

Application Number	10/828481-Conf. #4860
Filing Date	April 20, 2004
First Named Inventor	Carl H. JUNE
Art Unit	1633
Examiner Name	M. Leavitt

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
ML	CA	SAMBUCETTI et al. "NF- $\kappa$ B activation of the cytomegalovirus enhancer is mediated by a viral transactivator and by T cell stimulation," The EMBO Journal, 1989, pp. 4251-4258, Vol. 8, No. 13.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	03-07-2006
-----------------------	--	--------------------	------------

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/828481-Conf. #4860
				Filing Date	April 20, 2004
				First Named Inventor	Carl H. JUNE
				Art Unit	1633
				Examiner Name	M. Leavitt
Sheet	1	of	1	Attorney Docket Number	0036119.00140US3

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>2</sup> -Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>4</sup>

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. \*Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
ML	CA	Guba et al., "Interleukin-3 Gene Induction in Normal Human T Cells Via Stimulation of CD3 and CD28," Clinical Research, 37(4): 902A (1989)	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner:	Date:
Maric S. Leavitt	03-10-06